Adjuvant Therapy Based on Pathologic Response After Neoadjuvant

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04330430` - Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease	Phase 2
Withdrawn	`NCT04007588` - A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma	Phase 2
Recruiting	`NCT05171374` - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Completed	`NCT03620019` - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma	Phase 2
Recruiting	`NCT04562129` - IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients	Phase 2
Recruiting	`NCT04990726` - Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
Recruiting	`NCT05970497` - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05370807` - A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma	Phase 2
Recruiting	`NCT04045691` - Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Not yet recruiting	`NCT05070221` - Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis	Phase 1
Not yet recruiting	`NCT05068453` - Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis	Phase 1
Recruiting	`NCT03353402` - Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy	Phase 1
Recruiting	`NCT04513028` - Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma	N/A
Recruiting	`NCT05598853` - Intrathecal Double Checkpoint Inhibition	Phase 1
Recruiting	`NCT04521075` - A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	Phase 1/Phase 2
Recruiting	`NCT06425926` - Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT03153085` - A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma	Phase 2
Recruiting	`NCT03991130` - High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT04526899` - Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	Phase 2
Recruiting	`NCT06319196` - Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma	Phase 2

NCT number	NCT04741997
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact	Krystal Victoria
Phone	813-745-0218
Email	Krystal.Victoria@moffitt.org
Status	Recruiting
Phase	Early Phase 1
Start date	May 24, 2021
Completion date	January 2027

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms